DEVELOPMENT OF A HIGH-THROUGHPUT PROCESS FOR THE PRODUCTION OF DIAGNOSTIC MONOCLONAL ANTIBODIES (Q2035396)

From EU Knowledge Graph
Revision as of 14:34, 15 July 2020 by DG Regio (talk | contribs) (‎Changed an Item)
Jump to navigation Jump to search
Project in Italy financed by DG Regio
Language Label Description Also known as
English
DEVELOPMENT OF A HIGH-THROUGHPUT PROCESS FOR THE PRODUCTION OF DIAGNOSTIC MONOCLONAL ANTIBODIES
Project in Italy financed by DG Regio

    Statements

    0 references
    5,714.0 Euro
    0 references
    11,428.0 Euro
    0 references
    50.0 percent
    0 references
    15 November 2016
    0 references
    7 December 2018
    0 references
    3 December 2018
    0 references
    TAKIS SRL
    0 references
    0 references
    0 references

    41°53'35.95"N, 12°28'58.55"E
    0 references
    L'AZIENDA DI BIOTECNOLOGIE TAKIS PRODUCE IN MODO INNOVATIVO ED EFFICACE ANTICORPI MONOCLONALI PER CONTO PROPRIO E PER CONTO TERZI. SEBBENE MOLTO COMPETITIVA NEI PROTOCOLLI DI VACCINAZIONE, IL PROCESSO ATTUALE MANCA DI UN SISTEMA ROBOTIZZATO PER L (Italian)
    0 references
    THE BIOTECH COMPANY IS INNOVATIVE AND EFFECTIVE MONOCLONAL ANTIBODIES FOR OWN ACCOUNT AND FOR HIRE OR REWARD. ALTHOUGH HIGHLY COMPETITIVE IN VACCINATION PROTOCOLS, THE CURRENT PROCESS LACKS A ROBOTIC SYSTEM FOR (English)
    0 references

    Identifiers

    F83G17000640007
    0 references